SLC22A6

Solute carrier family 22 member 6 · Q4U2R8 · SLC22A6 on Sugi Atlas →

141,272 patent compounds predicted against SLC22A6, 108,766 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3418	0.62	3/20
SCHEMBL66842	0.62	3/20
SCHEMBL68873	0.62	3/20
Cefatrizine (SCHEMBL49503)	0.61	3/20
Cefotiam (SCHEMBL65480)	0.51	3/20
Cephalothin (SCHEMBL2990)	1.00	2/20
Cephaloridine (SCHEMBL3936)	1.00	2/20
Cefotaxime (SCHEMBL15410)	1.00	2/20
Cefotaxime (SCHEMBL15411)	1.00	2/20
Indole Acetate (SCHEMBL15553)	1.00	2/20
Indoxyl Sulfate (SCHEMBL15755)	1.00	2/20
Ceftriaxone (SCHEMBL23355)	1.00	2/20
Ceftriaxone (SCHEMBL23356)	1.00	2/20
Adefovir Dipivoxil (SCHEMBL29729)	1.00	2/20
Cefoperazone (SCHEMBL37056)	1.00	2/20
Cefamandole (SCHEMBL37287)	1.00	2/20
Adefovir (SCHEMBL49373)	1.00	2/20
Cefoperazone (SCHEMBL40452)	0.99	2/20
Ceftriaxone (SCHEMBL40850)	0.99	2/20
Cefotaxime (SCHEMBL41091)	0.98	2/20

Clinical trials — most relevant to SLC22A6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation	PHASE2/PHASE3	UNKNOWN
Treatment of Ectopic Calcification in Fahr's Disease or Syndrome	PHASE2	RECRUITING
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery	PHASE2	COMPLETED
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Levocarnitine for Dry Eye in Sjogren's Syndrome	PHASE2	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Cancer and Hearing Loss Related in Children	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - United States Only	nan	ENROLLING_BY_INVITATION
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient	nan	UNKNOWN
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Autonomic Function in Patients With COPD	nan	COMPLETED
Effect of Pharmacogenetics on Imatinib Plasma Level and Response	nan	COMPLETED
Bile Acid Effects in Fetal Arrhythmia Study	nan	UNKNOWN
Genetics of Hyperuricemia Therapy in Hmong	nan	COMPLETED
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia	nan	COMPLETED
Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia	nan	COMPLETED
SLC6A1-NDD Prospective Longitudinal Natural History Study	nan	NOT_YET_RECRUITING
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias	nan	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Oxalate and Citrate	nan	RECRUITING
Coproporphyrine Isomers and Methotrexate Elimination	nan	COMPLETED
Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC22A6 binder may also engage these)

Protein	Name	Similarity
Q5RCH6	—	1.000	Q5RCH6 →
Q4W8A3	—	1.000	Q4W8A3 →
Q9TSY7	—	1.000	Q9TSY7 →
Q864Z3	—	0.996	Q864Z3 →
O35956	—	0.993	O35956 →
Q8MK48	—	0.993	Q8MK48 →
Q8VC69	—	0.990	Q8VC69 →
Q3ZAV1	—	0.985	Q3ZAV1 →
Q8CFZ5	—	0.981	Q8CFZ5 →
Q4W8A2	—	0.976	Q4W8A2 →
Q5R9C4	—	0.975	Q5R9C4 →
SLC22A8	Organic anion transporter 3	0.975	landscape →
A6NK97	—	0.974	A6NK97 →
A6QLW8	—	0.973	A6QLW8 →
Q1RPP5	—	0.973	Q1RPP5 →
SLC22A11	Solute carrier family 22 member 11	0.971	landscape →
Q9Y226	—	0.970	Q9Y226 →
A0A8B7HA97	—	0.970	A0A8B7HA97 →
Q70BM6	—	0.970	Q70BM6 →
Q8HY24	—	0.969	Q8HY24 →
Q5R540	—	0.969	Q5R540 →
Q5RLM2	—	0.968	Q5RLM2 →
Q3YAW7	—	0.967	Q3YAW7 →
Q9Y694	—	0.967	Q9Y694 →
Q9BYW1	—	0.967	Q9BYW1 →
Q6NYN7	—	0.966	Q6NYN7 →
Q80UJ1	—	0.966	Q80UJ1 →
Q8N4F4	—	0.966	Q8N4F4 →
Q8VCA0	—	0.966	Q8VCA0 →
G1SZD9	—	0.963	G1SZD9 →